Comparative Approach to Define Increased Regulatory T Cells in Different Cancer Subtypes by Combined Assessment of CD127 and FOXP3
Table 2
Patient characteristics for Treg-cell assessment in lymph node biopsies.
(a) Follicular lymphoma (lymph node)
ID
Gender
Age (yr)
Stage
Therapy
Treg (%)
44
m
59
FL I
no tx
23.9
45
m
46
FL I
no tx
13.4
46
f
58
FL I
no tx
26.8
47
m
73
FL II
no tx
19.6
48
f
66
FL II
no tx
20.0
49
m
59
FL II
no tx
13.2
50
m
57
FL II
no tx
22.5
51
m
65
FL II
no tx
37.5
(b) Hodgkin’s disease (lymph node)
ID
Gender
Age (yr)
Entity
Therapy
Treg (%)
52
f
53
HD (ns)
no tx
37.8
53
m
44
HD (ns)
no tx
16.8
54
m
51
HD (ns)
no tx
43.9
55
m
19
HD (ns)
no tx
18.5
56
m
34
HD (ns)
no tx
16.9
57
f
25
HD (mc)
no tx
12.4
(c) Healthy donors (reactive lymph nodes)
ID
Gender
Age (yr)
Treg (%)
58
m
35
4.9
59
f
18
11.7
60
f
17
4.9
61
m
22
9.7
62
f
45
16.7
63
m
39
8.9
64
m
24
14.0
Patient characteristics including gender, age at analysis, first diagnosis, therapy, and frequency of Treg cells. (f: female, m: male; no tx: no therapy; mc: mixed cellularity; ns: nodular sclerosing).
